WO2015017423A3 - Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture - Google Patents

Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture Download PDF

Info

Publication number
WO2015017423A3
WO2015017423A3 PCT/US2014/048645 US2014048645W WO2015017423A3 WO 2015017423 A3 WO2015017423 A3 WO 2015017423A3 US 2014048645 W US2014048645 W US 2014048645W WO 2015017423 A3 WO2015017423 A3 WO 2015017423A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified release
manufacture
methods
acid derivative
folic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/048645
Other languages
French (fr)
Other versions
WO2015017423A2 (en
Inventor
Gopi Venkatesh
Micael Guillot
Jin-Wang Lai
Michael Gosselin
Nicole BEINBORN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Priority to JP2016531822A priority Critical patent/JP2016525576A/en
Priority to EP14832791.9A priority patent/EP3027178A2/en
Priority to CA2919213A priority patent/CA2919213A1/en
Publication of WO2015017423A2 publication Critical patent/WO2015017423A2/en
Publication of WO2015017423A3 publication Critical patent/WO2015017423A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to an oral stabilized modified release pharmaceutical dosage form containing L-methylfolate calcium, which is primarily absorbed from proximal small intestine via a saturable human proton-coupled folate transporter (h-PCFT) mediated transport intended as monotherapy for the treatment of patients with MDDs and/or diagnosed with dysthymia, schizophrenia, or degenerative dementia of the Alzheimer type.
PCT/US2014/048645 2013-07-29 2014-07-29 Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture Ceased WO2015017423A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2016531822A JP2016525576A (en) 2013-07-29 2014-07-29 Stabilized modified release folic acid derivative composition, therapeutic use thereof and production method thereof
EP14832791.9A EP3027178A2 (en) 2013-07-29 2014-07-29 Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
CA2919213A CA2919213A1 (en) 2013-07-29 2014-07-29 Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361859627P 2013-07-29 2013-07-29
US61/859,627 2013-07-29

Publications (2)

Publication Number Publication Date
WO2015017423A2 WO2015017423A2 (en) 2015-02-05
WO2015017423A3 true WO2015017423A3 (en) 2015-04-02

Family

ID=52390702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/048645 Ceased WO2015017423A2 (en) 2013-07-29 2014-07-29 Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture

Country Status (5)

Country Link
US (1) US20150030676A1 (en)
EP (1) EP3027178A2 (en)
JP (1) JP2016525576A (en)
CA (1) CA2919213A1 (en)
WO (1) WO2015017423A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
WO2016185412A1 (en) * 2015-05-20 2016-11-24 Nestec S.A. Immediate release formulations
EP3355865B8 (en) 2015-09-29 2025-02-19 Merz Pharmaceuticals, LLC Sustained release compositions of 4-aminopyridine
CN114903860A (en) * 2021-02-07 2022-08-16 江苏开元药业有限公司 Pteroylglutamic acid tablet and preparation method thereof
WO2023084460A1 (en) * 2021-11-11 2023-05-19 Ln Laboratories Pvt Ltd Oral dispersible film comprising l-methylfolate and process thereof
WO2024240775A1 (en) * 2023-05-25 2024-11-28 Chiesi Farmaceutici S.P.A. Pharmaceutical dosage forms for pulsatile release
IT202300027360A1 (en) * 2023-12-20 2025-06-20 Lesaffre & Cie SOLID FOLATE FORMULATIONS
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038343A1 (en) * 2006-07-06 2008-02-14 Kristina King Pharmaceutical composition containing a tetrahydrofolic acid
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
WO2012030927A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120128771A1 (en) * 2005-05-02 2012-05-24 Venkatesh Gopi M Timed, pulsatile release systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (en) * 1999-04-15 2004-04-15 Eprova Ag Stable crystalline salts of 5-methyl tetrahydrofolic acid.
WO2006099237A1 (en) * 2005-03-10 2006-09-21 Sciele Pharma, Inc. Nutritional preparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128771A1 (en) * 2005-05-02 2012-05-24 Venkatesh Gopi M Timed, pulsatile release systems
US20080038343A1 (en) * 2006-07-06 2008-02-14 Kristina King Pharmaceutical composition containing a tetrahydrofolic acid
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
WO2012030927A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management

Also Published As

Publication number Publication date
CA2919213A1 (en) 2015-02-05
WO2015017423A2 (en) 2015-02-05
JP2016525576A (en) 2016-08-25
US20150030676A1 (en) 2015-01-29
EP3027178A2 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
WO2015017423A3 (en) Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
CY1123391T1 (en) (2S)-N-[(1S)-1-CYANO-2-PHYNYLATHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS INHIBITORS OF DIPEPTYLYPEPTIDASE I
IN2014DN03206A (en)
EA201591371A1 (en) Pyridine derivatives as easily degraded inhibitors ROCK
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
EA033544B1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
MX368387B (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue.
EP2849738C0 (en) HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF LUNG DISEASES
JO3122B1 (en) Derivatives of Astra-1,3,5 (10), 16-Tetraine-3-carboxamide, preparations, pharmaceutical preparations, and use for the preparation of drugs
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
EA201500112A1 (en) 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES
EA032951B1 (en) Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same
HK1217092A1 (en) Therapeutic compounds and uses thereof
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201891931A1 (en) NEW INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE GAMMA
PH12015500823A1 (en) Modified release formulations for oprozomib
HK1206347A1 (en) Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
IN2014DN09240A (en)
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX394106B (en) INHALED PREPARATION OF ISOGLYCYRRHIZIC ACID OR SALT THEREOF, AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832791

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2919213

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016531822

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014832791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014832791

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832791

Country of ref document: EP

Kind code of ref document: A2